CLSA has released a research report indicating that INNOVENT BIO (01801) reported product revenue of RMB 8.2 billion for the first half of 2026, representing a 55% year-on-year increase and far surpassing the market consensus of RMB 6.9 billion.
Given earlier market concerns that anti-corruption measures could negatively impact the pharmaceutical sector's first-half performance, this product sales result is particularly encouraging. The firm believes this will act as a positive catalyst for the stock price today.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments